MedTrace Logo

Primary Immunodeficiency in Kuwait

NCT03618147 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 314

Last updated 2019-09-09

Study results available
· View outcomes & findings →

Summary

* Background/Rationale: Epidemiological data about Primary Immunodeficiency Disorders (PIDD) in Kuwait is needed to better understand peculiarities and to compare them with other regions and ethnicity.
* Study hypothesis: PIDD is relatively common in Kuwait compared to populations from different geographic areas. The distribution of PIDD in Kuwait is different from other geographic areas with more severe forms being more frequent.
* Brief inclusion and exclusion criteria of study participants: PIDD patients presented at different clinics/hospital in Kuwait. Patients with secondary immunodeficiencies (drug induced, virus induced, and immunodeficiency associated with metabolic disorders... ect), will be excluded
* Estimated sample size of the study: All patients who were registered in KNPIDR since 2004 will be included in the study along with the new patients who will be recruited during the study period.
* Primary objectives:

* Determine the prevalence and frequency of different PIDD in Kuwait
* Identify clinical presentation patterns for PIDD in Kuwait
* Identify natural history of PIDD in Kuwait
* Help to asses epidemiology of PIDD in Kuwait
* Determine particularities about PIDD affecting the population in Kuwait
* Determine the health impact of PIDD in Kuwait
* Development of strategies to improve the care and the quality of life of patients with PIDD

Conditions

  • Primary Immune Deficiency Disorder

Sponsors & Collaborators

  • Kuwait Society for Allergy and Clinical Immunology

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-16
Primary Completion
2019-05-01
Completion
2019-05-01

Countries

  • Kuwait

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03618147 on ClinicalTrials.gov